Loading
Led the trial proving that an anti-GD2 antibody improves survival in high-risk neuroblastoma.
Alice Yu is Professor of Pediatrics at UC San Diego and an immunotherapy investigator with the Children's Oncology Group (COG). A paediatric oncologist specialising in neuroblastoma and anti-GD2 antibodies, she was study chair of COG ANBL0032, the randomised trial of ch14.18 (dinutuximab) with GM-CSF and IL-2 that established anti-GD2 immunotherapy in high-risk neuroblastoma. Her papers report the anti-GD2 antibody with GM-CSF, interleukin-2 and isotretinoin for neuroblastoma in the New England Journal of Medicine and the long-term follow-up of that phase III study in Clinical Cancer Research. Her work made a monoclonal antibody against GD2 part of paediatric immunotherapy.
| Title | Journal | Year |
|---|---|---|
| Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma | New England Journal of Medicine | 2010 |
| Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032 | Clinical Cancer Research | 2021 |
Shares COG ANBL0032, GD2 (disialoganglioside), Dinutuximab (ch14.18) / dinutuximab beta, Children's Oncology Group (COG).
Shares GD2 (disialoganglioside), Dinutuximab (ch14.18) / dinutuximab beta, Neuroblastoma (paediatric).
Shares COG ANBL0032, Dinutuximab (ch14.18) / dinutuximab beta, Neuroblastoma (paediatric).
Shares Dinutuximab (ch14.18) / dinutuximab beta, Neuroblastoma (paediatric).
Shares GD2 (disialoganglioside), Dinutuximab (ch14.18) / dinutuximab beta, Children's Oncology Group (COG), Neuroblastoma (paediatric).
Shares Dinutuximab (ch14.18) / dinutuximab beta, Children's Oncology Group (COG), Neuroblastoma (paediatric).
Shares Children's Oncology Group (COG), Neuroblastoma (paediatric).
Shares GD2 (disialoganglioside), Neuroblastoma (paediatric), Monoclonal antibodies.